Catalogue Number: AB00742-3.0-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | Cytotactin; GMEM; GP 150-225; Glioma-associated-extracellular matrix antigen; Hexabrachion; JI; Myotendinous antigen; Neuronectin; Tenascin-C |
| Shipping Condition: | Blue Ice |
| Unit(s): | 1 mg |
| Host name: | Mouse |
| Clone: | I-81C6 (Neuradiab) |
| Isotype: | IgG2b |
| Immunogen: | This therapeutic antibody was generated by radiolabelling, using a modified Iodo-gen procedure, murine anti-human tenascin Mab 81C6. Mab 81C6 was raised by immunizing mice with the glial fibrillary acidic protein-positive human glioma cell line U-251 MG (Bourdon et al, 1983). |
| Application: | ELISA, CCA, RadIod |
TNC
3371
P24821
Purified
Recombinant Monoclonal
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
This I-labelled murine antibody binds tenascin, which is over expressed in certain cancers, and as a result has been used to deliver a radiation boost to the surgically created resection cavity (SCRC) margin; administration of a patient-specific radioactivity dose of this antibody into the SCRC enabled the consistent achievement of a 44-Gy boost to the SRC 2cm margin, associated with reduced neurotoxicity and improved survival relative to fixed dosing approaches (Reardon, 2008). In addition, a humanized form of this I-labeled murine antibody, generated by joining the 81C6 variable regions to the constant region of human IgG2, has been characterised through binding assays, cross-competition assays and immunoreactivity analysis, and has exhibited superior uptake in human glioma xenografts compared with its murine 81C6 parent (Zalutsky, 1996).